Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
News Jun 09, 2009
Progenics Pharmaceuticals, Inc. has announced that its collaborator, Ono Pharmaceutical Co., Ltd., Osaka, Japan has begun clinical testing in Japan of RELISTOR® (methylnaltrexone bromide) subcutaneous injection, the first-in-class medicine approved in the U.S., Canada, the European Union, Australia and Latin American countries for the treatment of opioid-induced constipation.
Ono has exclusive rights to subcutaneous RELISTOR in Japan, where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid-induced constipation. RELISTOR is being developed and commercialized in the rest of the world by Progenics and Wyeth Pharmaceuticals, a division of Wyeth.
ONO-3849 is being developed in Japan according to the regulatory agency guidelines of Japan’s Ministry of Health, Labor and Welfare, and will be evaluated in Japanese patients with opioid-induced constipation.
“Our collaboration with Ono exemplifies Progenics’ corporate strategy of maximizing market access to RELISTOR through key geographic development and commercialization partnerships,” said Paul J. Maddon, M.D., Ph.D., Progenics’ Founder, Chief Executive Officer and Chief Science Officer. “We believe the advancement of RELISTOR into clinical studies in Japan demonstrates a shared commitment of both organizations to providing patients in Japan who suffer from opioid-induced constipation access to this first-in-class product, if approved.”
In October of last year, Progenics announced an agreement by which Ono has rights in Japan to the subcutaneous form of RELISTOR, and is responsible for developing and commercializing subcutaneous RELISTOR in Japan, including conducting the clinical development necessary to support regulatory marketing approval.
Under the agreement, Progenics received an upfront fee, and is entitled to commercial and development milestones, as well as royalties on sales of RELISTOR in Japan.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018